References
- Balsells M, García-Patterson A, Gich I, et al. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94:4284–4291.
- Di Cianni G, Volpe L, Lencioni C, et al. Prevalence and risk factors for gestational diabetes assessed by universal screening. Diabetes Res Clin Pract. 2003;62:131–137.
- Kragelund Nielsen K, Damm P, Kapur A, et al. Risk factors for hyperglycaemia in pregnancy in Tamil Nadu, India. PLoS One. 2016;11:e0151311.
- Escudero C, González M, Acurio J, et al. The role of placenta in the fetal programming associated to gestational diabetes. In: Gestational diabetes—causes, diagnosis and treatment [Internet]. Croatia: InTech; 2013. p. 135–162
- Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.
- Guzmán-Hernández ML, Potter G, Egervári K, et al. Secretion of VEGF-165 has unique characteristics, including shedding from the plasma membrane. MBoC. 2014;25:1061–1072.
- Sultan SA, Liu W, Peng Y, et al. The role of maternal gestational diabetes in inducing fetal endothelial dysfunction. J Cell Physiol. 2015;230:2695–2705.
- Singh VP, Bali A, Singh N, et al. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14.
- Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14:453.
- Shang M, Lin L. IADPSG criteria for diagnosing gestational diabetes mellitus and predicting adverse pregnancy outcomes. J Perinatol. 2014;34:100–104.
- Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123–4131.
- Perrin RM, Konopatskaya O, Qiu Y, et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422–2427.
- Zhao M, Xie WK, Bai YJ, et al. Expression of total vascular endothelial growth factor and the anti-angiogenic VEGF 165 b isoform in the vitreous of patients with retinopathy of prematurity. Chin Med J (Engl). 2015;128:2505–2509.
- Lappas M. Markers of endothelial cell dysfunction are increased in human omental adipose tissue from women with pre-existing maternal obesity and gestational diabetes. Metab Clin Exp. 2014;63:860–873.
- Radaelli T, Varastehpour A, Catalano P, et al. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. Diabetes. 2003;52:2951–2958.
- Poniedziałek-Czajkowska E, Mierzyński R, Szymula D, et al. Intercellular adhesion molecule and endogenous NOS inhibitor: asymmetric dimethylarginine in pregnant women with gestational diabetes mellitus. J Diabetes Res. 2016;2016:1.
- Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276:7614–7620.
- Wan TT, Li XF, Sun YM, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Biomed Pharmacother. 2015;74:145–147.
- Guosheng L, Hongmei S, Chuan N, et al. The relationship of serum AGE levels in diabetic mothers with adverse fetal outcome. J Perinatol. 2009;29:483–488.
- Barbosa JH, Oliveira SL, Seara LT. The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arq Bras Endocrinol Metabol. 2008;52:940–950.